Abstract：Objective: To study the efficacy of hydroxychloroquine sulfate in the treatment of Sjogren’s syndrome (SS) and the effects on levels of serum interleukin-17 (IL-17), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and immunoglobulin G (IgG). Methods: A total of 194 SS patients admitted to our hospital from March 2017 to March 2020 were randomly and evenly divided into observation group and control group, with 97 cases in each group. Both groups were given methylprednisolone on the basis of symptomatic treatment, and observation group was additionally given hydroxychloroquine sulfate during treatment, and the treatment lasted 3 months. The treatment effects and adverse reactions were observed in the two groups, and the Schirmer Test (ST), salivary flow rate (SFR) and levels of serum IL-17, ESR, CRP and IgG were detected before and after treatment. Results: The treatment effects in observation group were significantly better than those in control group (P<0.05), and the effective rates of the two groups were 86.60% and 75.26% (P<0.05). There were no significant differences in ST and SFR between the two groups before treatment (P>0.05). After treatment, ST and SFR were significantly increased (P<0.05), and the differences of ST and SFR in observation group after treatment were higher than those in control group (P<0.05). There were no significant differences in the levels of serum IL-17, ESR, CRP and IgG between the two groups before treatment (P>0.05). After treatment, the levels of serum IL-17, ESR, CRP and IgG were significantly reduced (P<0.05), and the differences of IL-17, ESR, CRP and IgG before and after treatment in observation group were higher than those in control group (P<0.05). The incidence rates of adverse reactions in observation group and control group were 16.49% and 12.37% respectively (P>0.05). Conclusion: Hydroxychloroquine sulfate in the adjuvant treatment of SS can effectively reduce the levels of serum IL-17, ESR, CRP and IgG, thereby improving the symptoms and enhancing the treatment effects.
[1] Vivino FB,Bunya VY,Massaro-Giordano G,et al.Sjogren's syndrome:an update on disease pathogenesis,clinical manifestations and treatment[J].Clin Immunol,2019,203:81~121. [2] 邵勤,吴斌.原发性干燥综合征的治疗进展[J].中国免疫学杂志,2018,34(1):144~148,157. [3] Zhang LW,Zhou PR,Wei P,et al.Expression of interleukin-17 in primary sjogren's syndrome and the correlation with disease severity:a systematic review and meta-analysis[J].Scand Immunol,2018,87(4):e12649. [4] Manzo C.Polymyalgia rheumatica (PMR) with normal values of both erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration at the time of diagnosis in a centenarian man:a case report[J].Diseases,2018,6(4):84. [5] St Clair EW,Baer AN,Wei C,et al.Clinical efficacy and safety of baminercept,a lymphotoxin β receptor fusion protein,in primary sjogren's syndrome:results from a phase II randomized,double-blind,placebo-controlled Trial[J].Arthritis Rheumatol,2018,70(9):1470~1480. [6] 中华医学会风湿病学分会.干燥综合征诊治指南(草案)[J].中华风湿病学杂志,2003,7(7):446~448. [7] Wang SQ,Zhang LW,Wei P,et al.Is hydroxychloroquine effective in treating primary sjogren's syndrome:a systematic review and meta-analysis[J].BMC Musculoskelet Disord,2017,18(1):186. [8] Verstappen GM,Corneth OBJ,Bootsma H,et al.Th17 cells in primary Sjogren's syndrome:Pathogenicity and plasticity[J].J Autoimmun,2018,87:16~25. [9] 王柏山.原发性干燥综合征患者外周血Th17细胞及CXCL13检测及其临床意义[J].国际检验医学杂志,2018,39(14):47~49,53. [10] 饶志华,曾光.硫酸羟氯喹联合甲氨蝶呤与来氟米特治疗类风湿关节炎临床疗效分析[J].中国煤炭工业医学杂志,2018,21(2):118~121. [11] 赵嘉英,黄松涛,严宏莉,等.干燥综合征睡眠质量及其相关因素[J].中华临床免疫和变态反应杂志,2019,13(4):313~317.
2021, Vol. 27 
冀公网安备13080202000677号